ZNF217 and breast cancer: The induction of miR-503 in response to estrogen stimulation has anti-proliferative effects, likely through its repression of both CCND1 and ZNF217. Combined with the information that miR-503 is down-regulated in human cancers, these results indicate that miR-503 presents a new candidate therapeutic option for the treatment of breast cancer.